ArticleCureus2024
Neuromyelitis Optica Spectrum Disorder With Unilateral Retrobulbar Neuritis: A Case Report.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuromyelitis optica spectrum disorder (NMOSD) includes conditions with autoimmune genesis, which are manifested by attacks of optic neuritis (ON) and transverse myelitis (TM), and also express aquaporin 4 (NMO-IgG) or myelin oligo-endocytic glycoprotein (MOGAb) antibodies. In rare cases, the disease may also have a clinical presentation with only TM, without ON or with ON, without TM. These conditions are also included in the spectrum. We present a case of a 50-year-old patient with complaints of blurry vision in the left eye, neck pain, and numbness of the hands a few months prior to hospitalization. After a consultation with an ophthalmologist, magnetic resonance imaging (MRI) of the brain was performed, and findings showed left ON. Serological findings showed antibodies for aquaporin 4 with a ratio of 1:100, which is a pathognomic marker for NMOSD. Upon admission to the clinic, the complaints persisted. The neurological status revealed decreased vision of the left eye, pain in the Valleix points in the cervical region, and hyperesthesia including dermatomes C5-C8, more prominent for the right arm. Routine blood tests showed leukocytosis, neutrophilia, and lymphocytosis. Additional virology studies were performed to rule out neuroborreliosis, neurosyphilis, and human immunodeficiency virus (HIV). MRI of the cervical spine revealed dural sac compression from degenerative spinal disease. Electromyography (EMG) showed radiculopathy at the C5-C8 levels and neuropathy of n. ulnaris sinistra and n. medianus dextra. Consultation with an ophthalmologist revealed a decrease in the left eye visus. The treatment plan consisted of methylprednisolone 1000 mg for five days and gastroprotection with famotidine 40 mh p.o. Further consultations with the ophthalmologist were done in the following days to monitor the visual status of the patient. After completion of the diagnostic and treatment plan, slight recovery of the visus and reversal of the pain symptomatology was reported. Based on the history, clinical findings, ophthalmologic examination, brain and neck imaging (MRI), and laboratory results (NMO-IgG ratio 1:100 ), NMOSD with left retrobulbar neuritis (Devic's disease) was concluded as the final diagnosis. Multiple sclerosis (MS; retrobulbar neuritis) first attack, systemic connective tissue disease (systemic lupus erythematosus, Sjögren's syndrome, and antiphospholipid syndrome), and neuro-infection were discussed. Clinical suspicion of intracranial tumors was ruled out. Corticosteroids and gastroprotectors were prescribed for oral use under the supervision of a neurologist. Regular check-ups were performed. The reported case of NMOSD with unilateral optic nerve involvement is a rare condition in neurological practice. It requires an individualized approach to diagnose and apply treatment. Patient follow-up is a key starting point toward gathering more information about autoimmune processes in the central nervous system (CNS) and toward finding faster, more reliable, and cheaper clinical and instrumental methods of diagnosis, which in turn may lead to more timely initiation of treatment, proportionally leading to improvement in the patient's quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.